AEterna Zentaris

AEterna Zentaris is a drug development company focused on oncology and endocrinology treatments. Its product pipeline includes compounds at all stages of development, from drug discovery to marketed products. In oncology, the key areas of focus are Phase III cyclophosphamide-containing regimens for multiple myeloma, Phase II regimens for various cancers including metastatic colorectal cancer, and a Phase II program for AEZ-108 in advanced endometrial and advanced ovarian cancers, with potential developments in other cancer indications. In endocrinology, the company plans to reactivate the Phase III trial of AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for diagnosing adult GH deficiency (AGHD).